Peptide News Digest

Gilead Bixlenvo HIV Approval, Priovant Lisraya Dermatomyositis, Moderna $2B Raise, DualityBio-Genentech ADC $1B+

FDA clears Gilead Bixlenvo for HIV and Priovant Lisraya for dermatomyositis, Moderna raises $2B for cancer vaccine, DualityBio inks Genentech ADC deal.

10 stories · Covering regulatory, industry

Editor's Note

Friday delivered a heavy regulatory day paired with a busy business-development calendar and thin peptide-first headlines. Two FDA approvals landed Wednesday-Thursday — Gilead's Bixlenvo (bictegravir plus lenacapavir, the first single-tablet regimen built around a capsid inhibitor) and Priovant's Lisraya (brepocitinib, the first oral targeted therapy for dermatomyositis at a $35,000 monthly list) — while a third, Pfizer-BioNTech's XFG-adapted Comirnaty, quietly rolled into the fall vaccination cycle. Moderna followed the August 19 intismeran Phase 3 melanoma win with a $2 billion convertible-notes raise Wednesday to fund the neoantigen program, DualityBio pulled a $45 million upfront plus $1 billion in milestones from Genentech for its DUPAC novel-payload ADC platform, and Osivax paired its nucleoprotein-targeted influenza vaccine OVX836 with GC Biopharma's marketed GC FLU for a next-generation combination. ITM's Aug 28 PDUFA for 177Lu-edotreotide (ITM-11) passed without approval on the back of the August 7 CRL that cited manufacturing and third-party facility issues rather than clinical data. And BioXcel filed Chapter 11, with Teva taking stalking-horse status at $57.5 million for the dexmedetomidine sublingual film.

Regulatory

FDA Approves Gilead Bixlenvo (Bictegravir 75 mg / Lenacapavir 50 mg), First Single-Tablet Regimen Built Around a Capsid Inhibitor for Virologically Suppressed HIV Adults

The FDA approved Gilead Sciences (NASDAQ: GILD) Bixlenvo (bictegravir 75 mg / lenacapavir 50 mg, a once-daily single-tablet HIV regimen) on Wednesday August 27, 2026 for adults with HIV-1 who are virologically suppressed on a stable antiretroviral regimen for at least 6 months and have no history of treatment failure or known resistance to bictegravir or lenacapavir. Approval was based on the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials presented at CROI 2026, both of which met non-inferiority for virologic suppression at Week 48 with a tolerable safety profile. Lenacapavir is Gilead's first-in-class HIV-1 capsid inhibitor (already approved as long-acting subcutaneous Sunlenca), and Bixlenvo is the first oral single-tablet regimen anchored on capsid inhibition. Dosing requires a two-day initiation period with Sunlenca before switching to Bixlenvo alone. The approval extends the single-tablet regimen category to an estimated 5%+ of U.S. HIV-suppressed adults on complex multi-pill regimens who could not previously use one-tablet options.

#gilead #gild #bixlenvo #bictegravir #lenacapavir #capsid-inhibitor #hiv #single-tablet-regimen #artistry-1 #artistry-2 #sunlenca #non-peptide
Regulatory

FDA Approves Priovant Lisraya (Brepocitinib) 30 mg for Adult Dermatomyositis, First Oral Targeted Therapy at $35,000 Per Month List Price

Roivant Sciences (NASDAQ: ROIV) subsidiary Priovant Therapeutics announced FDA approval of Lisraya (brepocitinib 30 mg once daily, a first-in-class TYK2/JAK1 dual selective inhibitor) on Wednesday August 27, 2026 for adults with dermatomyositis (DM), an autoimmune inflammatory myopathy with skin involvement and few effective targeted therapies. Approval was based on the 52-week Phase 3 VALOR trial (241 patients, the longest and largest interventional DM study), where 55% of Lisraya patients achieved moderate-or-better improvement on the Total Improvement Score with minimal-or-no steroid use versus 30% on placebo. VALOR results were published in NEJM in March 2026 with dermatology secondary endpoints in JAMA Dermatology in August 2026. List price is $35,000 for a 30-day supply, with a $0/month patient support program for eligible patients. Brepocitinib was originally discovered by Pfizer and licensed to Priovant. Not a peptide; the approval matters here because dermatomyositis is one of several autoimmune indications where peptide immunomodulators (thymalfasin, thymosin alpha-1 analogs) had been discussed in earlier decades before being displaced by targeted small-molecule and biologic approaches.

#roivant #roiv #priovant #lisraya #brepocitinib #tyk2-jak1 #dermatomyositis #valor-trial #35000-per-month #pfizer-original-discovery #non-peptide
Industry

Moderna Prices $2 Billion Convertible Notes Offering to Fund Cancer Vaccine Business After Intismeran Phase 3 Win

Moderna (NASDAQ: MRNA) announced Wednesday August 27, 2026 a private placement of $2 billion in convertible senior notes due 2032, with proceeds directed to the cancer vaccine business (led by intismeran autogene / mRNA-4157, the individualized neoantigen therapy that encodes up to 34 tumor-specific neoantigen peptides per patient) and to repay existing debt. The raise follows the Wednesday August 19 announcement that the Phase 3 INTerpath-001 melanoma trial of intismeran plus Keytruda met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival, which added roughly $44.5 billion in market cap to MRNA in a single session as shares surged 177%. Moderna is advancing intismeran in nine total Phase 2 and Phase 3 trials across melanoma, NSCLC, bladder cancer, and renal cell carcinoma, and the raise positions the company to accelerate manufacturing scale-out and expansion into new tumor types.

#moderna #mrna #intismeran #mrna-4157 #cancer-vaccine #2-billion-convertible-notes #neoantigen-peptides #interpath-001 #keytruda #manufacturing-scale-out
Industry

DualityBio and Genentech Sign $45 Million Upfront, $1 Billion+ Milestone ADC Deal on DUPAC Novel-Payload Platform Targeting TOPO1 Resistance

DualityBio (HKEX: 9606) announced Friday August 28, 2026 a global collaboration and license agreement with Genentech (Roche Group) to develop next-generation antibody-drug conjugates on DualityBio's proprietary DUPAC (DualityBio Unique Payload Antibody Conjugate) platform. Terms: $45 million upfront to DualityBio plus more than $1 billion in aggregate development, regulatory, and commercial milestone payments across all programs, with tiered royalties on annual net sales. DualityBio handles discovery through Phase Ia; Genentech takes over global clinical development and commercialization. The DUPAC platform is one of DualityBio's four proprietary ADC platforms and is dedicated to payloads with novel mechanisms of action designed to address resistance to existing topoisomerase inhibitor-based ADCs (Trodelvy, Enhertu, Datroway, and successors). The deal is Genentech's second Asia-based ADC alliance in a week and continues the pattern of large pharma buying diverse payload chemistries as ADC-first-line combinations expand.

#dualitybio #9606-hk #genentech #roche #dupac-platform #antibody-drug-conjugate #45-million-upfront #1-billion-milestones #topo1-resistance #novel-payload
Regulatory

FDA Approves Pfizer-BioNTech XFG-Adapted Comirnaty for 2026-2027 Season for Ages 65+ and High-Risk Adults and Pediatrics 5-64

Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced Thursday August 27, 2026 FDA approval of the supplemental Biologics License Application for their 2026-2027 XFG-adapted Comirnaty (COVID-19 mRNA vaccine) for adults ages 65 and older and for individuals 5-64 with at least one underlying condition that puts them at high risk for severe COVID-19 outcomes. The XFG-adapted formula was designed to elicit strong immune responses against XFG, XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1, and other contemporary lineages. Shipping to distribution centers began immediately after approval. The XFG-adapted authorization for the 2026-2027 respiratory season provides continuity with Pfizer-BioNTech's annual mRNA vaccine cadence and, indirectly, reinforces the manufacturing and lipid-nanoparticle infrastructure that Moderna is now leaning on for the intismeran neoantigen peptide-encoding cancer vaccine program.

#pfizer #pfe #biontech #bntx #comirnaty #xfg-variant #2026-2027-formula #covid-vaccine #mrna-vaccine #high-risk-adults
Industry

Osivax and GC Biopharma Sign Global Collaboration Combining OVX836 Nucleoprotein-Targeted Broad-Spectrum Vaccine With GC FLU for Next-Generation Seasonal Influenza

Osivax (clinical-stage French biopharmaceutical) and GC Biopharma (South Korean vaccine maker, KRX: 006280) announced Thursday August 27, 2026 a long-term collaboration to develop and commercialize a next-generation seasonal influenza vaccine candidate combining OVX836 (Osivax's broad-spectrum influenza A vaccine targeting the highly conserved nucleoprotein NP, in Phase 2 development) with GC FLU (GC Biopharma's marketed inactivated influenza vaccine). Osivax receives a non-exclusive sublicensable global license (excluding Japan and Korea) to use GC FLU in combination with OVX836 and will lead global development and commercialization outside South Korea; GC Biopharma retains exclusive Korean rights, receives royalties, and ensures long-term supply of GC FLU. Financial terms were not disclosed. The NP-targeted broad-spectrum approach positions the combination to address the annual antigenic-drift problem that has kept seasonal influenza vaccine efficacy in the 30-60% range and drives interest in peptide- and protein-based broadly conserved epitope vaccines.

#osivax #gc-biopharma #ovx836 #nucleoprotein #influenza-vaccine #gc-flu #broad-spectrum-vaccine #next-generation-flu-vaccine #conserved-epitope
Industry

ProFound Therapeutics Receives $35 Million Gates Foundation Investment Commitment for Preeclampsia and Eclampsia Drug Target and Biomarker Discovery

ProFound Therapeutics (Flagship Pioneering company, Cambridge, Massachusetts) announced Thursday August 27, 2026 an investment commitment of up to $35 million from the Bill and Melinda Gates Foundation for preeclampsia and eclampsia drug target and biomarker discovery. Structure: $20 million upfront plus $15 million tied to experimental milestones. ProFound will apply its ProFoundry platform (a proteomics-scale discovery engine that identifies previously undetected proteins from tissue and serum) and its agentic AI tooling to placental tissue and serum samples from women with the conditions in search of first-in-class protein drug targets and biomarkers. Preeclampsia affects roughly 5-8% of pregnancies globally and remains a leading cause of maternal and fetal morbidity and mortality; there are currently no approved disease-modifying drugs. The Gates commitment continues the foundation's pattern of directing capital toward maternal health gaps that private capital has under-served.

#profound-therapeutics #flagship-pioneering #gates-foundation #35-million-investment #preeclampsia #eclampsia #profoundry-platform #agentic-ai #protein-drug-discovery #maternal-health
Industry

BioXcel Therapeutics Files Chapter 11, Enters $57.5 Million Stalking-Horse Asset Sale Agreement With Teva for Dexmedetomidine Sublingual Film

BioXcel Therapeutics (NASDAQ: BTAI) filed for Chapter 11 bankruptcy protection Thursday August 27, 2026 after telling investors it lacked cash to fund operations through the end of August despite securing a bridge loan earlier the same week. Teva Pharmaceutical Industries (NYSE: TEVA) signed a stalking-horse asset sale agreement Friday August 28, 2026 to acquire BioXcel's lead neuroscience asset for $57.5 million upfront plus up to $67.5 million in milestone payments through a court-supervised auction. The lead asset is a novel dexmedetomidine sublingual film under FDA review for at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, with a PDUFA target action date of November 14, 2026. The stalking-horse bid sets the floor price for competing bidders. Teva positioned the acquisition as consistent with its 'Pivot to Growth' strategy and disciplined business development approach.

#bioxcel-therapeutics #btai #chapter-11 #teva #stalking-horse-bid #57-5-million-upfront #dexmedetomidine #sublingual-film #agitation #schizophrenia #bipolar #pdufa-november-14-2026
Regulatory

ITM 177Lu-Edotreotide (ITM-11) August 28 PDUFA Passes Without Approval Under Earlier August 7 Complete Response Letter Citing Manufacturing Issues

ITM Isotope Technologies Munich SE's August 28, 2026 PDUFA target action date for 177Lu-edotreotide (ITM-11, a synthetic somatostatin-analog peptide-radioconjugate for gastroenteropancreatic neuroendocrine tumors) passed without an FDA approval decision, following the August 7, 2026 Complete Response Letter that cited Chemistry, Manufacturing, and Controls items and unresolved conditions at a third-party commercial manufacturing facility as the sole basis for the refusal. The FDA explicitly did not raise clinical or nonclinical safety or efficacy concerns, and did not request additional clinical data. ITM has stated it plans to resubmit the NDA once the manufacturing and facility items are addressed. The Phase 3 COMPETE trial (309 patients, first- or second-line inoperable progressive Grade 1 or Grade 2 GEP-NETs) had met its primary endpoint with a significant progression-free survival benefit over everolimus and a significantly higher objective response rate. The CRL is the second on the ITM-11 program and delays direct commercial competition with Novartis Lutathera (177Lu-DOTATATE, the incumbent peptide-radioconjugate for GEP-NETs).

#itm-radiopharma #itm-11 #177lu-edotreotide #gep-nets #somatostatin-analog #peptide-radioconjugate #complete-response-letter #cmc-deficiencies #compete-trial #lutathera-competitor #novartis-lutathera
Industry

Roivant Q1 Fiscal 2027 Update Confirms Lisraya Launch Team, Distribution, and Payer Coverage as U.S. Commercial Launch Begins August 28

Alongside the FDA approval announcement Wednesday August 27, 2026, Roivant Sciences (NASDAQ: ROIV) filed an 8-K disclosure and hosted a conference call Friday August 28, 2026 confirming that Priovant Therapeutics has fielded a dermatology-and-rheumatology-focused sales force, contracted with major specialty pharmacy distributors, and secured initial payer coverage sufficient to begin U.S. commercial launch on August 28. Priovant is a Pfizer-Roivant joint venture (Roivant 75%, Pfizer 25%) that was created in 2022 specifically to advance brepocitinib in dermatomyositis, cutaneous lupus, and non-infectious uveitis. Beyond Lisraya, Priovant's brepocitinib program continues in Phase 3 for cutaneous lupus (VALIANT) with topline data expected in H1 2027 and in Phase 2 for non-infectious uveitis. The launch is a signal event for the Roivant 'Vant' model, in which spin-out subsidiaries develop and commercialize discrete assets while remaining consolidated within the parent. Not a peptide; included because the JAK/TYK2 inhibitor category continues to displace older peptide-based immunomodulation approaches in autoimmune disease.

#roivant #roiv #priovant #vant-model #lisraya-launch #brepocitinib #dermatomyositis-launch #valiant-cutaneous-lupus #non-infectious-uveitis #pfizer-jv #non-peptide